Salt of fused heterocyclic derivative and crystal thereof
The present invention provides 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid choline salt having excellent solubility and storage stability.
1. A method for treating a sex hormone-dependent disease selected from the group consisting of benign prostatic hypertrophy, hysteromyoma, endometriosis, metrofibroma, precocious puberty, amenorrhea, premenstrual syndrome, dysmenorrhea, polycystic ovary syndrome, hirsutism, short stature, infertility, irritable bowel syndrome and prostate cancer, comprising administering an effective amount of a compound represented by the formula:
2. The method of claim 1 , wherein said sex-hormone dependent disease is endometriosis.
3. The method of claim 1 , wherein said sex-hormone dependent disease is hysteromyoma.
4. The method of claim 1 , wherein said sex-hormone dependent disease is prostate cancer.
5. The method of claim 1 , wherein said compound is administered orally.
6. The method of claim 1 , wherein said compound is crystalline.
7. The method of claim 1 , wherein said compound has characteristic peaks at diffraction angles (2θ(°)) of 7.1, 11.5, 19.4, 20.3, 21.5, 22.0, 22.6, 23.5, and 26.2 in a powder X-ray diffraction diagram.
8. The method of claim 1 , wherein said compound has characteristic peaks at chemical shift values (δ(ppm)) of 155.8, 149.8, 145.3, 118.0, 113.7, 111.6, 110.3, 98.1, 69.8, 58.7, 57.1, and 55.5 in a 13 C solid-state NMR spectrum.
9. The method of claim 1 , wherein said compound has characteristic peaks at chemical shift values (δ (ppm)) of −131.6, −145.2, and −151.8 in a 19 F solid-state NMR spectrum.